JP2022520061A - 治療薬および治療方法 - Google Patents

治療薬および治療方法 Download PDF

Info

Publication number
JP2022520061A
JP2022520061A JP2021546264A JP2021546264A JP2022520061A JP 2022520061 A JP2022520061 A JP 2022520061A JP 2021546264 A JP2021546264 A JP 2021546264A JP 2021546264 A JP2021546264 A JP 2021546264A JP 2022520061 A JP2022520061 A JP 2022520061A
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
methyl
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021546264A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022520061A5 (cg-RX-API-DMAC7.html
Inventor
ツェン,グァンロン
チョウ,ダオホン
パル,プラティク
リュウ,シンギ
ツムリ,ディネシュ
フ,ワンイ
チャン,ペイイ
リュ,ドンウェン
ユアン,ヤクシア
チャン,スアン
Original Assignee
ユニバーシティ オブ フロリダ リサーチ ファウンデーション,インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティ オブ フロリダ リサーチ ファウンデーション,インコーポレイティド filed Critical ユニバーシティ オブ フロリダ リサーチ ファウンデーション,インコーポレイティド
Publication of JP2022520061A publication Critical patent/JP2022520061A/ja
Publication of JP2022520061A5 publication Critical patent/JP2022520061A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2021546264A 2019-02-08 2020-02-07 治療薬および治療方法 Pending JP2022520061A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962803299P 2019-02-08 2019-02-08
US62/803,299 2019-02-08
PCT/US2020/017364 WO2020163823A2 (en) 2019-02-08 2020-02-07 Therapeutic agents and methods of treatment

Publications (2)

Publication Number Publication Date
JP2022520061A true JP2022520061A (ja) 2022-03-28
JP2022520061A5 JP2022520061A5 (cg-RX-API-DMAC7.html) 2023-05-23

Family

ID=71948254

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021546264A Pending JP2022520061A (ja) 2019-02-08 2020-02-07 治療薬および治療方法

Country Status (8)

Country Link
US (1) US20220169628A1 (cg-RX-API-DMAC7.html)
EP (1) EP3920923A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022520061A (cg-RX-API-DMAC7.html)
KR (1) KR20210137025A (cg-RX-API-DMAC7.html)
CN (1) CN113660937A (cg-RX-API-DMAC7.html)
AU (1) AU2020218367A1 (cg-RX-API-DMAC7.html)
CA (1) CA3127501A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020163823A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023510885A (ja) * 2020-01-15 2023-03-15 ユニバーシティ オブ フロリダ リサーチ ファウンデーション,インコーポレイティド 治療用物質および処置方法

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12673106B2 (en) 2020-08-28 2026-07-07 University Of Florida Research Foundation, Incorporated Modulators of nuclear receptor subfamily 4 group A member 1 (NR4A1) and uses thereof
JP2024505562A (ja) 2021-02-02 2024-02-06 レス ラボラトイレス セルビエル 選択的bcl-xl protac化合物及び使用の方法
US20240408085A1 (en) * 2021-09-01 2024-12-12 Xizang Haisco Pharmaceutical Co., Ltd. Compound for degradation of bcl-2 family proteins and medical application thereof
US20240398764A1 (en) * 2021-10-12 2024-12-05 University Of Florida Research Foundation, Incorporated Methods of treating diseases associated with senescent cell accumulation
CN118660886A (zh) 2021-12-09 2024-09-17 佛罗里达大学研究基金公司 用于治疗癌症的bcl-xl/bcl-2双重降解剂
CA3240051A1 (en) 2021-12-30 2023-07-06 Beigene Switzerland Gmbh Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
CN116396288B (zh) * 2022-01-04 2026-04-03 上海科技大学 基于bcl-2家族蛋白配体化合物开发的蛋白降解剂及它们的应用
AU2023264537A1 (en) 2022-05-06 2024-11-14 Treeline Biosciences, Inc. Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
PE20250007A1 (es) 2022-05-06 2025-01-07 Treeline Biosciences Inc Degradadores bcl-xl-heterobifuncionales de tetrahidroisoquinolina
EP4519260A1 (en) 2022-05-06 2025-03-12 Treeline Biosciences, Inc. Tetrahydroisoquinoline heterobifunctional bcl-xdegraders
US20260092057A1 (en) * 2022-05-12 2026-04-02 Kymera Therapeutics, Inc. Bcl-xl/bcl-2 degraders and uses thereof
CN115028679B (zh) * 2022-08-11 2022-11-15 深圳湾实验室 一种具有Cyclophilin A降解活性的PROTAC化合物及其制备方法与应用
CN120659777A (zh) * 2022-10-03 2025-09-16 佛罗里达大学研究基金公司 募集Cereblon的Bcl-xL/Bcl-2双重降解剂
WO2024078581A1 (en) * 2022-10-12 2024-04-18 Appicine Therapeutics (Hk) Limited Selective bcl-xl protac compounds and uses thereof
CN120569222A (zh) * 2023-01-18 2025-08-29 苏州宜联生物医药有限公司 包含bcl-2家族蛋白降解剂的抗体药物偶联物及其制备方法和用途
CN121652220A (zh) * 2023-02-17 2026-03-13 正大天晴药业集团股份有限公司 含有三氟甲磺酰基的化合物
AU2024378690A1 (en) 2023-11-07 2026-05-07 Treeline Biosciences, Inc. Tetrahydroisoquinoline heterobifunctional bcl-x l degraders
IL327973A (en) 2023-11-07 2026-06-01 Treeline Biosciences Inc Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
KR20260111020A (ko) 2023-11-07 2026-07-14 트리라인 바이오사이언시스, 인크. 테트라히드로이소퀴놀린 이종이작용성 bcl-xl 분해제
WO2026015489A1 (en) * 2024-07-08 2026-01-15 University Of Florida Research Foundation, Incorporated Bcl-xl/bcl-2 dual degraders and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017024317A2 (en) * 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2017184995A1 (en) * 2016-04-21 2017-10-26 Bioventures, Llc Compounds that induce degradation of anti-apoptotic bcl-2 family proteins and the uses thereof
WO2017197055A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
JP2018512449A (ja) * 2015-03-18 2018-05-17 アルビナス インコーポレイテッド 標的タンパク質の分解向上のための化合物および方法
WO2018106870A1 (en) * 2016-12-08 2018-06-14 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating cdk4/6-mediated cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7973161B2 (en) * 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
JP6817962B2 (ja) * 2015-01-20 2021-01-20 アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. ターゲティングされたアンドロゲン受容体分解のための化合物および方法
EP3337476A4 (en) * 2015-08-19 2019-09-04 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
US20240398764A1 (en) * 2021-10-12 2024-12-05 University Of Florida Research Foundation, Incorporated Methods of treating diseases associated with senescent cell accumulation
CN118660886A (zh) * 2021-12-09 2024-09-17 佛罗里达大学研究基金公司 用于治疗癌症的bcl-xl/bcl-2双重降解剂

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018512449A (ja) * 2015-03-18 2018-05-17 アルビナス インコーポレイテッド 標的タンパク質の分解向上のための化合物および方法
WO2017024317A2 (en) * 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2017184995A1 (en) * 2016-04-21 2017-10-26 Bioventures, Llc Compounds that induce degradation of anti-apoptotic bcl-2 family proteins and the uses thereof
WO2017197055A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
WO2018106870A1 (en) * 2016-12-08 2018-06-14 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating cdk4/6-mediated cancer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023510885A (ja) * 2020-01-15 2023-03-15 ユニバーシティ オブ フロリダ リサーチ ファウンデーション,インコーポレイティド 治療用物質および処置方法

Also Published As

Publication number Publication date
WO2020163823A2 (en) 2020-08-13
EP3920923A2 (en) 2021-12-15
KR20210137025A (ko) 2021-11-17
CN113660937A (zh) 2021-11-16
AU2020218367A1 (en) 2021-08-12
WO2020163823A8 (en) 2020-10-01
WO2020163823A3 (en) 2020-10-29
CA3127501A1 (en) 2020-08-13
US20220169628A1 (en) 2022-06-02
EP3920923A4 (en) 2022-10-26

Similar Documents

Publication Publication Date Title
US20220169628A1 (en) Therapeutic agents and methods of treatment
JP7829523B2 (ja) 多環式tlr7/8アンタゴニスト及び免疫障害の治療におけるそれらの使用
AU2020267169B2 (en) Processes of making and crystalline forms of a MDM2 inhibitor
US12441722B2 (en) Therapeutic agents and methods of treatment
EP3655401B1 (en) Tlr7/8 antagonists and uses thereof
US9187434B2 (en) Substituted 1,5-benzodiazepinones compounds
US10519152B2 (en) Compounds and their use in treating cancer
JP2025530275A (ja) 汎kras阻害剤化合物
CN106255679B (zh) 用作nav通道抑制剂的杂环化合物及其用途
KR102653190B1 (ko) 고 활성 sting 단백질 작용제 화합물
CA2922532A1 (en) Aminoheteroaryl benzamides as kinase inhibitors
US9133126B2 (en) Fluoroalkyl dibenzoazepinone compounds
CN116783183A (zh) 作为vhl抑制剂用于治疗贫血和癌症的1-(2-(4-环丙基-1h-1,2,3-三唑-1-基)乙酰基)-4-羟基-n-(苄基)吡咯烷-2-甲酰胺衍生物
KR20240118146A (ko) 암 치료용 bcl-xl/bcl-2 이중 분해제
TW202540125A (zh) 雙環雜芳基化合物
JP2024508728A (ja) Nlrp3阻害剤としての化合物
JP7611591B2 (ja) Pd-l1拮抗薬化合物
TW202321244A (zh) 一種Wnt通路抑制劑化合物
HK40060209A (en) Therapeutic agents and methods of treatment
CN116507617B (zh) 作为vhl抑制剂的1-(2-(4-环丙基-1h-1,2,3-三唑-1-基)乙酰基)-4-羟基吡咯烷-2-甲酰胺衍生物
KR20180134401A (ko) 예를 들어 알츠하이머병을 치료하기 위한 선택적 BACE1 억제제로서 N-[3-[2-아미노-5-(1,1-디플루오로에틸)-4,4a,5,7-테트라히드로푸로[3,4-d][1,3]옥사진-7a-일]-4-플루오로-페닐]-5-(트리플루오로메틸)피리딘-2-카르복스아미드 및 그의 (4aR,5S,7aS) 이성질체
NZ753956B2 (en) Processes of making and crystalline forms of a mdm2 inhibitor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230512

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240227

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240917